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Abstract 
Aim: It is unknown how the heart distinguishes various overloads, such as exercise or 
hypertension, causing either physiological or pathological hypertrophy. We hypothesize that 
alpha calcitonin gene-related peptide (!CGRP), known to be released from contracting 
skeletal muscles, is key at this remodeling.  
Methods: The hypertrophic effect of !CGRP was measured in vitro (cultured cardiac 
myocytes) and in vivo (magnetic resonance imaging) in mice. Exercise performance was 
assessed by determination of maximum oxygen consumption and time to exhaustion. Cardiac 
phenotype was defined by transcriptional analysis, cardiac histology and morphometry. 
Finally, we measured spontaneous activity, body fat content, blood volume, hemoglobin mass 
and skeletal muscle capillarization and fiber composition. 
Results: While !CGRP exposure yielded larger cultured cardiac myocytes exercise-induced 
heart hypertrophy was completely abrogated by treatment with the peptide antagonist 
CGRP(8-37). Exercise performance was attenuated in !CGRP-/- mice or CGRP(8-37) treated 
wild type mice but improved in animals with higher density of cardiac CGRP receptors 
(CLR-tg). Spontaneous activity, body fat content, blood volume, hemoglobin mass, muscle 
capillarization and fiber composition were unaffected whereas heart index and ventricular 
myocyte volume were reduced in !CGRP-/- mice and elevated in CLR-tg. Transcriptional 
changes seen in !CGRP-/- (but not CLR-tg) hearts resembled maladaptive cardiac phenotype.  
Conclusions: !CGRP released by skeletal muscles during exercise is a hitherto unrecognized 
effector directing the strained heart into physiological instead of pathological adaptation. 
Thus, !CGRP agonists might be beneficial in heart failure patients. 
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Introduction 
A long-standing question is why the heart adapts to different overloads by committing itself 
to either physiological or pathological hypertrophy. A widely believed, though never proven, 
tenet is that intermittent stimuli, such as exercise, promote physiological hypertrophy. In 
contrast, chronic stresses such as hypertension are thought to always induce pathological 
hypertrophy. However, according to a recent study (Perrino et al., 2006) it is the nature of the 
overload - independent of its chronicity - that determines the cardiac phenotype.  
Adequate physical performance depends on the type, intensity and frequency of previous 
exercise that affects entire organs, blood vessels as well as sub-cellular structures (Hoppeler 
and Weibel, 1998). During exercise, acute nutrient and oxygen delivery to skeletal muscles is 
controlled by the sympathetic nervous system and local mechanisms based on proton, lactate, 
potassium and CO2 release (Boushel, 2010). Since about 50% of maximum exercise capacity 
depends on cardiac output (Q) (Andersen and Saltin, 1985), among the adaptive mechanisms 
activated with endurance training is physiological, exercise-induced heart hypertrophy (i.e. 
“athlete’s heart”). While the specific mechanisms that drive physiological myocardial 
hypertrophy in response to exercise are unknown they appear to be distinct from those of 
pathological hypertrophy - even when resulting in the same increase of ventricular mass 
(Perrino et al., 2006). Physiological heart hypertrophy could partly rest on a feedback loop, 
known as “metaboreflex”, that adjusts the circulation to the needs of the exercising skeletal 
muscles by monitoring their activity and metabolic state through mechanoreceptors (group III 
or A" fibers) and chemoreceptors (group IV or non-myelinated C fibers) (Boushel, Mitchell 
et al., 1983, Amann et al., 2011). Activated A" and C fibers release !CGRP (Schmelz and 
Petersen, 2001), the plasma levels of !CGRP correlate tightly with exercise load (Schifter et 
al., 1995, Lind et al., 1996, Hasbak et al., 2002) and !CGRP binding sites have been detected 
throughout the heart (Sigrist et al., 1986). Whereas !CGRP generally causes positive inotropy 
on atria (Ishikawa et al., 1988) some authors (Huang et al., 1999) but not others (Ishikawa et 
al., 1988) found positive inotropic effects of the peptide on the ventricles. Moreover, 
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culturing cardiac myocytes in the presence of CGRP promotes hypertrophy of these cells 
(Bell et al., 1995, Bell et al., 1997). In vivo, systemic !CGRP might exert positive inotropic 
effects also by activating directly sympathetic postganglionic neurons (Katori et al., 2005) 
similar as described for !CGRP’s positive chronotropic action (Kunz et al., 2007, Fisher et 
al., 1983).  
The localization of !CGRP receptors, the positive inotropy of !CGRP on atria and maybe 
also on ventricles as well as the fact that increasing plasma levels of this peptide correlate 
specifically with the physical strain applied (Schifter et al., 1995, Lind et al., 1996, Hasbak et 
al., 2002) are all in line with the notion of exercising skeletal muscles might acting as an 
endocrine organ that releases !CGRP and supports acutely the increase in cardiac output. In 
addition, as we show here, this hormonal signal might aid the heart to discern exercise from 
other loads and provoke the physiological phenotype of cardiac hypertrophy. Thus, CGRP 
might need to be added to the continuously growing list of myokins.  
 
Materials and Methods 
Animals 
Mice globally deficient for !CGRP were kindly provided by Ron B. Emeson (Lu et al., 
1999). Mice transgenic for the calcitonin receptor-like receptor (CLR-tg) overexpress a V5 
(GKPIPNPLLGDST) tagged rat CLR under control of the mouse smooth-muscle !-actin 
promoter (Kunz et al., 2007). C57BL6 (BL6) matched to the !CGRP-/- mice and non-
transgenic littermates (BL6xDBA2) of CLR-tg mice served as respective wild type control 
groups or were used for the training experiments. Male mice (except for the measurement of 
spontaneous activity and body fat content) at an age between 12 and 16 weeks were used for 
all experiments. The experiments in this study conformed to the 'European Convention for the 
Protection of Vertebrate Animals used for Experimental and other Scientific Purposes' 
(Council of Europe No 123, Strasbourg 1985) as well as institutional and local governmental 
guidelines. 
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Surgery 
Telemetric blood pressure sensors (TA11PA-C10, DataSciences International) were 
implanted as described (Schuler et al., 2010) to enable continuous recording of arterial blood 
pressure and heart rate during the exercise experiments. Anesthetized mice were equipped 
with a femoral artery catheter and allowed to recover from anesthesia for 15 min for 
determination of arterial blood gases and blood volume as described (Schuler et al., 2010). 
Lower legs and hearts of mice, some perfusion fixed with paraformaldehyde (PFA) in PBS, 
were harvested for CGRP receptor autoradiography (unfixed), HE staining (4% PFA), muscle 
and capillary ATPase histochemistry (2% PFA) and succinatedehydrogenase staining 
(unfixed) as described (Riddle et al., 1993, Rosenblatt et al., 1987). 
 
Exercise tests 
Exercise tests were conducted as described with continuous monitoring of oxygen 
consumption and carbon dioxide production for VO2max and respiratory exchange ratio (RER) 
determination (Schuler et al., 2010). Ten minutes prior to these tests, mice were injected s.c. 
either with 200#l PBS (control) or 20nmol CGRP(8-37) (Bachem) dissolved in 200#l PBS.  
In addition, 14 C57BL6 mice were subjected to 3-weeks treadmill exercise with five weekly 
45-min units. The training program was initiated at treadmill speed of 16 m/min and 
inclination of 5° and increased weekly to maximum values of 20 m/min and 9°. Fifteen 
minutes before each training session half of the mice were injected with 20nmol CGRP(8-37) 
dissolved in 200#l PBS and the other half with 200#l PBS.  
Before and after the training period magnetic resonance imaging (Bruker PharmaScan 47/16) 
of the heart was performed. A cine FLASH sequence was acquired (TE/TR = 1.8/57 ms, an 
RF pulse angle ! = 10°) using the self-gating technique IntraGate (ParaVision 5.0, Bruker 
BioSpin). Eight contiguous 1-mm thick slices were acquired in short axis orientation over the 
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entire heart with a spatial resolution of 98 x 98 µm2. Time points of maximal and minimal 
ventricular dimensions defined endsystolic and enddiastolic ventricle volume respectively. 
 
Heart analysis 
Cardiac hypertrophy in the genetically modified mice was assessed by three different methods 
i.e. determination of heart index (heart weight to body weight or tibia length ratio), cross 
sectional areas of cardiac myocytes, and volume of isolated, PFA-fixed cardiac myocytes. To 
this end cardiac myocytes displaying central nuclei in H&E stained sections were selected for 
measurement of the cross sectional area with an image analyzing system (MCID 7.0, 
Ontario). The volume of about 2000 freshly isolated cardiac myocytes (cf. next paragraph), 
which had been fixed immediately by adding an equal volume of 4% PFA in PBS was 
determined with a Coulter counter (Beckman Z2) equipped with a 200#m aperture. 
Cardiac phenotype was assessed with cDNA obtained from RNA extracts (RNeasy, Qiagen) 
after Proteinase K (Promega) and on-membrane DNase I digestion (Qiagen)) of the whole 
heart by droplet digital PCR (ddPCR, Bio-Rad) according to the manufactures instruction. To 
this end, using the cDNA end-point PCR with always 41 cycles were performed after splitting 
each sample into 12000 - 15000 droplets. Next the percentage of positive droplets was 
determined and used to calculate the copy number per #l. All primer / probe pairs used 
produced less than 1% of intermediate droplets suggesting high specificity. As negative 
control transcription reactions of isolated RNA were also performed without reverse 
transcriptase. In addition, each primer / probe pair was tested on genomic mouse DNA and 
under these conditions none of them showed positive droplets. As pathological heart 
hypertrophy is characterized by an increased ratio of the Myh6 (!-myosin heavy chain) to 
Myh7 ("-myosin heavy chain) expression, increased Nppa (natriuretic peptide type A) 
expression and increased collagen IIIa to collagen IaIb expression ratio ddPCR reactions were 
conducted using mouse “best coverage” TaqMan® kits from Applied Biosystems for Myh6, 
Myh7, Nppa, collagen IaIb and collagen IIIa (cf. Table 1). Abundance of Nppa amplicons 
was normalized with calsequestrin amplicons as the expression of this gene remains 
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unaffected in non-failing as well as failing hearts (Hullin et al., 1999). RNA quality was 
assessed before transcribing it to cDNA (iScript, Bio-Rad) by gel analysis and measurement 
of the A260/A280 ratio. Only samples with a band intensity ratio of the 28S/18S ribosomal 
RNA >1.5 and a A260/A280 ratio > 1.95 were accepted.  
Collagen protein content of the hearts was assed on formalin-fixed paraffin-embedded 
sections according to a previously published protocol (Lopez-De Leon and Rojkind, 1985). 
Briefly, using a commercially available kit (Sirius red/Fast green Collagen Staining kit, 
Chondrex) sections were stained simultaneously for total protein (Fast Green) and collagen 
(Picrosirius Red). The dye was subsequently eluted from the section and the optical density 
(OD) of the eluate was read at 540 and 605 nm using a spectrophotometer. The amount of 
collagen per total protein was calculated as Col/prot = ((OD540 – (OD605 * 0.291)) / 0.0378) / 
(OD605 / 0.00204) according to the manufacturer’s instructions.  
Finally, heart muscle tissue samples were processed for electron microscopy by fixation in a 
6.25% solution of glutaraldehyde as previously described (Hoppeler et al., 1973). Capillary 
number, fiber number and fiber cross-sectional area were estimated at a final magnification of 
1500. Five micrographs per block (20 micrographs per sample) were taken in consecutive 
frames of slotted grids (type R, 100 A, Veco Co, Amsterdam, The Netherlands) yielding >100 
muscle profiles for analysis in each sample. A magnification of 24,000 was used for 
estimation of the volumes of mitochondria per unit volume of muscle fiber as described 
(Hoppeler et al., 1973). Ten micrographs per block were taken and projected and fitted with 
quadratic line grids. Point counting was performed with an A 100 grid (100 test points) for 
the lower magnification and with a B 36 grid (144 test points) for the higher magnification 
(Hoppeler et al., 1973). Estimates of variables were obtained according to standard 
stereological procedures. 
 
Cell culture 
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Adult murine cardiac myocytes were isolated as described (Kabaeva et al., 2008) and cultured 
for 3.5 days with or without 250nMol !CGRP or 250nMol calcitonin (Sigma). At the end of 
this cultivation cells were fixed and analyzed for their volume as described above. 
 
Cardiac !CGRP binding sites and !CGRP expression 
!CGRP binding sites in atria and ventricles of the genetically modified mice were determined 
by receptor autoradiography using 125I labeled !CGRP (PerkinElmer) as described (Henke et 
al., 1985). Adjacent sections were used for immunautoradiography against CGRP (primary 
antibody rabbit anti-CGRP IgG: 1:2000, Chemicon; secondary antibody: 125I labeled anti-
rabbit IgG, PerkinElmer: specific activity adjusted to 60nCi per slide) as described (Zeller et 
al., 1995). Unspecific binding was assessed by pre-incubation of the sections with 1#M 
unlabelled !CGRP and omission of the primary antibody, respectively. 
 
Muscle analysis 
Capillary contacts and percentage of type II fibers in the gastrocnemius and anterior tibial 
muscle (TA) were measured according to Rosenblatt et al. (Rosenblatt et al., 1987). Oxidative 
fibers were also visualized as described (Riddle et al., 1993). 
 
Estimate of adipose and lean tissue weight  
The ratio of lean to fat body mass was determined using computer tomography at a resolution 
of 100µm per pixel and slice distance of 1mm acquired throughout the whole mouse body as 
described (Hillebrand et al., 2010).  
 
Measurement of spontaneous activity 
Home cage activity was measured in pair-housed mice (pairing always the same genotype, 4 
x two mice of CLR-tg, !CGRP-ko, BL6xDBA2 and BL6 each). All test trials started at 3 pm 
(lights on) and were digitally recorded for 24h with infrared sensitive cameras in the absence 
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of a human observer. The recorded 24h video material was analysed using the ObserverXT® 
software (Noldus, Wageningen, Netherlands) (Jirkof et al., 2012). 
 
Statistics 
All data were analyzed with Excel or the GraphPad PRISM 4 Software (version 4.01) using 
ANOVA and two-sided Students t-test or non-parametric Kruskal-Wallis test in case the 
numbers of values were not equal for all groups and with Bonferroni’s or Dunn’s post hoc test 
respectively. P values below 0.05 were considered significant. 
 
Results 
!CGRP deficiency and CLR overexpression do not affect blood parameters, basal metabolic 
and cardio vascular parameters, heart muscle composition, skeletal muscle microanatomy, 
body fat content and spontaneous activity. 
No differences in resting acid base status and, more importantly, blood volume or total 
hemoglobin were detected between the different mouse lines (Table 2). Basal oxygen 
consumption, respiratory exchange ratio (RER), mean arterial blood pressure or heart rate 
were also indistinguishable among the animals used for the exercise tests (Table 3, cf. also to 
Fig. 1). No differences between the investigated mouse lines could be detected regarding the 
volume density of mitochondria or myofibrils in cardiac myocytes (Table 4). Whereas 
skeletal muscle fiber composition and capillary contacts remained unaffected by the genetic 
manipulations and yielded similar values compared to previous data (Gassmann et al., 2008) 
(Table 4) body fat content was lower in !CGRP-/- and BL6 animals compared to CLR-tg and 
BL6xDBA2 controls (Table 5). This greater degree of leanness in !CGRP-/- and BL6 mice 
might result from their approximately 30% higher spontaneous activity (Table 5). As !CGRP 
deficiency or CLR overexpression did not affect spontaneous activity or body fat content 
compared to the respective wt control (Table 5), the greater degree of leanness in CGRP-/- 
mice apparently results from the genetic BL6 background. 
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!CGRP deficiency is associated with cardiac hypotrophy whereas CLR overexpression 
results in cardiac hypertrophy. 
Despite exhibiting the same spontaneous activity, heart indices (heart weight normalized to 
body weight or tibia length) were, relative to the respective wt control, significantly reduced 
in !CGRP-/- mice and elevated in CLR-tg mice (Table 4). Accordingly, !CGRP-/- mice had 
significantly smaller and CLR-tg mice significantly larger cardiac myocyte volumes as well 
as cellular cross sectional areas (Table 4). 
 
Spontaneous exercise performance is reduced in !CGRP-/- mice and increased in CLR-tg 
mice. 
Compared to their respective wild type controls maximal oxygen consumption (VO2max) was 
7% lower in !CGRP-/- mice and 13% higher in CLR-tg mice. Moreover, treatment of 
BL6xDBA2with the !CGRP antagonist CGRP(8-37) decreased their VO2max by 7% (Fig. 1a). 
Due to some post-surgical problems only two CLR-tg mice could be measured after 
pretreatment with CGRP(8-37) but in these mice VO2max (151 ±3.96 ml/min/kg) as well as 
time to exhaustion (TTE; 68 ±6.88 min) was also lower compared to PBS pretreated CLR-tg 
mice (VO2max: 159 ±7.02 ml/min/kg and TTE: 81 ±10.65 min, cf. Fig. 1a & 1b). TTE 
measured one day later was shortened by 70% in !CGRP-/- and prolonged by 45% in CLR-tg 
mice compared to the respective control mice. Again, treatment of BL6xDBA2mice with 
CGRP(8-37) reduced TTE in this case about by 34% (Fig. 1b). At VO2max respiratory 
exchange ratio was the same in all animals suggesting equal exhaustion in all groups (Fig. 
1c). 
Compared to BL6xDBA2 control mice, mean arterial blood pressure (MAP) at VO2max was 
highest in CLR-tg mice whereas BL6xDBA2 mice pretreated with CGRP(8-37) displayed 
lower MAP values at VO2max (Fig. 1d). Heart rates did not differ between BL6xDBA2, 
BL6xDBA2 treated with CGRP(8-37) and CLR-tg. In contrast to the unaltered MAP at 
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VO2max, heart rate was suppressed in !CGRP-/- mice compared to their control group (BL6, 
Fig. 1d & 1e), which fits to the observation of Lu et al. made previously in a simple 
swimming test (Lu et al., 1999). Compared to BL6xDBA2 controls, at VO2max O2-pulse was 
higher in CLR-tg and reduced in BL6xDBA2 after treatment with CGRP(8-37) whereas the 
rate pressure product was higher in CLR-tg mice (Fig. 1f &  1g). 
 
!CGRP signaling promotes cardiac hypertrophy.  
In line with previous reports (Bell et al., 1997, Bell et al., 1995) cultured cardiac myocytes of 
adult BL6 acquired 11% larger volumes within 3.5 days when 250nmol !CGRP were added 
to the medium (final concentration: 25nM). In contrast, culturing cardiac myocytes for the 
same time with 250nmol calcitonin (final concentration: 25nM), a related peptide without 
affinity to CGRP receptors had no effect on their size (Fig. 2a & 2b).  
Endurance training of BL6 mice doubled TTE in both groups irrespective of treatment with 
PBS or CGRP(8-37) prior to each training session (data not shown). However, the cross 
sectional area of the cardiac myocytes was significantly smaller in CGRP(8-37) treated 
animals (Fig. 2c) relative to PBS injected controls. Accordingly, in the latter cohort of 
animals endurance training triggered significant enlargement (12%) of the ventricular muscle 
volume whereas it was unchanged in CGRP(8-37) treated animals (Fig. 2d). In addition, the 
remodeling index (ventricular muscle / enddiastolic volume (De Castro et al., 2007)) was 
significantly decreased in CGRP(8-37) but nearly unchanged in PBS treated mice when 
comparing pre- and post-training measures (Fig. 2e).  
 
Myocardial !CGRP binding sites are increased in CLR-tg mice. 
Using autoradiography and quantitative image analysis we found, in line with others (Sigrist 
et al., 1986, Franco-Cereceda et al., 1987, Mulderry et al., 1985), more CGRP and !CGRP 
binding sites in atria compared to ventricles (Fig. 3). Importantly, CLR-tg atria and ventricles 
displayed significantly more !CGRP binding sites than those of BL6xDBA2 suggesting 
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CLR-tg hearts to be more sensitive to systemic !CGRP than hearts of wt littermates. BL6 
mice and !CGRP-/- mice did not differ in atrial 125I-!CGRP binding sites while ventricles of 
!CGRP-/- mice showed less binding (Fig. 3a). Moreover cardiac CGRP expression was the 
same in all mouse lines except for !CGRP-/- mice that showed, as expected, CGRP 
immunoreactivity close to background staining (Fig. 3b).  
 
Myocardial gene expression profile of !CGRP-/- mice resembles a mild pathological 
phenotype. 
Pathological hypertrophy is associated with re-expression of fetal genes e.g. a down-regulated 
transcription of myh6 (!-myosin heavy chain) together with an up-regulated transcription of 
myh7 ("-myosin heavy chain) and Nppa (natriuretic peptide type A) (Perrino et al., 2006). 
Compared to respective BL6 controls !CGRP-/- mice exhibited significantly increased 
Myh7/Myh6 expression ratio along with an intensified Nppa expression. In contrast, among 
CLR-tg heart transcript pools the myh7/myh6 expression ratio and Nppa expression tended to 
be reduced compared to wt mice (Fig. 4a). Thus, these data suggest a fetal re-programming of 
the general gene expression in !CGRP-/- hearts that accompanies the emergence of a 
pathological phenotype. In addition, we measured the collagen III to collagen I expression 
ratio that is also affected by cardiac stress. These measurements revealed a more than 2-fold 
increased collagen III/I expression ratio in the CGRP-/- mice with unchanged total (collagen I 
& III) expression. This expression pattern resembles a beginning pathological cardiac 
remodeling (Weber et al., 1993). In contrast, CLR-tg mice displayed no different collagen 
expression compared to their respective wt control (Fig. 4a). 
We also looked at the mRNA expression of these three marker genes in the hearts of the BL6 
mice subjected to 3 weeks of endurance training. Compared to BL6 mice treated with PBS, 
the Myh7/Myh6 expression ratio and Nppa expression were found not to be affected in mice 
treated with CGRP(8-37) prior to each training session although these markers were slightly 
elevated in CGRP(8-37) treated animals (Fig. 4b). In addition, we found lower total collagen 
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expression (collagen III + I) when pooling all trained mice and compared them to all pooled 
sedentary mice (29.1 ±12.5 vs. 47.6 ±6.3 copies/#l, p < 0.01). Regarding the peptide 
treatment there was no significant differences of collagen III/I expression ratio between the 
trained groups or the sedentary groups (Fig. 4b). 
Quantification of Picrosirius Red staining revealed no significant differences between the 
groups (data not shown). 
 
Discussion 
The present study sheds light on the ongoing debate regarding the adaptations of the heart to 
various stresses, such as exercise or hypertension, which trigger either physiological or 
pathological hypertrophy. Using either mice lacking !CGRP, mice overexpressing !CGRP-
receptors in the heart (CLR-tg) or treating mice with the specific !CGRP-receptor blocker 
CGRP(8-37) we show that !CGRP is a crucial regulator of maximum exercise capacity. 
These observations cannot be explained by different spontaneous activities, lean to fat body 
mass ratios, blood volumes, and muscle capillarization or fiber composition as neither 
!CGRP deficiency nor CLR overexpression affected these parameters. However, heart 
indices and myocyte volumes were decreased in !CGRP-/- mice and increased in CLR-tg 
mice. Interestingly, !CGRP-/- mice but not CLR-tg animals showed a fetal reprogramming 
expression profile in resemblance of a maladaptive cardiac phenotype (Perrino et al., 2006). 
In line with our in vitro findings whereby incubation with !CGRP resulted in significantly 
larger cardiac myocytes as seen by others (Bell et al., 1997, Bell et al., 1995), exercise-
induced heart hypertrophy in BL6 mice was abrogated by CGRP(8-37) treatment. Thus, 
!CGRP augments maximum exercise capacity not only by acutely triggering positive 
chronotropy and inotropy (Fisher et al., 1983, Ishikawa et al., 1988, Huang et al., 1999, Kunz 
et al., 2007) but also because the peptide appears to be the hormonal signal that enables  the 
heart to distinguish physiological from pathological stresses. 
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The long-standing hypothesis that chronic cardiac stresses such as hypertension, stenosis of 
the outflow tract and others induce pathological heart adaptation whereas exercise, as 
intermittent stress, results in physiological heart remodeling has recently been questioned 
when Perrino et al. (Perrino et al., 2006) demonstrated that in contrast to endurance training, 
intermittent aortic constriction of the same time scheme resulted in pathological hypertrophy. 
In addition, the Myh7/Myh6 expression ratio and Nppa expression indicating a maladaptive 
cardiac phenotype was massively and significantly increased by chronic but only marginally 
by intermittent transverse aortic constriction (Perrino et al., 2006). Accordingly, the adult 
!CGRP-/- mice in our study displayed a slight although significant increase of the 
Myh7/Myh6 expression ratio as well as Nppa expression. Other biomarkers of pathological 
heart hypertrophy include cardiac fibrosis with increased collagen expression as well as 
altered relative expression of collagen III and I. However, the collagen III/I ratio is further 
known to change according to type, intensity and duration of the pathology, and changes with 
time. Typically, a higher collagen I expression occurs during more severe and longer lasting 
pathologies, whereas higher relative collagen III expression results when the pathology is 
mild and of short duration (Eleftheriades et al., 1993, Carver et al., 1991, Weber et al., 1988). 
Moreover, increased collagen deposition, although to a much lower degree, is also found in 
exercise induced, physiological heart adaptation, again, in dependence of duration and 
intensity of the training protocol (Lindsay and Dunn, 2007, Eleftheriades et al., 1993, 
Guimaraes et al., 2012). Thus, this multiparametric impact on collagen synthesis and ratios 
makes moderately increased collagen expression quite difficult to interpret in regard to the 
type of cardiac adaptation. With these cautionary notes in mind, the observed ~2-fold 
increased collagen III/I expression ratio in the CGRP-/- mice with unchanged total collagen (I 
+ III) expression might indicate the beginning of a pathological cardiac remodeling process 
(Weber et al., 1993). Thus, cardiac adaptation in mice challenged by a lifelong !CGRP-
deficiency (!CGRP-/- model) might mimic the course of a mild pathological hypertrophy, in 
agreement with the reduced spontaneous exercise performance of these animals. Conversely, 
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bouts of !CGRP released from exercising skeletal muscles might specifically characterize 
physiological overload situations. Accordingly, the formation of an athlete’s heart, e.g. 
ventricular enlargement at an unchanged or slightly increased remodeling index (ratio 
between myocardial volume and enddiastolic volume), was observed after a three weeks 
training period in PBS injected BL6 mice but not in CGRP(8-37) injected BL6 mice. In these 
latter mice the myocardial volume remained unchanged whereas the remodeling index 
decreased significantly (Fig. 2d & 2e), which characterizes cardiac maladaptation (De Castro 
et al., 2007). Unfortunately, assessing cardiac function directly was not possible, Hence, we 
do not know whether altered diastolic or systolic functions or both accompany the differences 
in exercise performance or heart geometry observed in the various experimental groups. 
Functional !CGRP-receptors in cardiac myocytes of rats or mice have been demonstrated 
previously (Huang et al., 1999) and consist of the CLR, a seven-transmembrane domain 
(7TM) protein, and the receptor activity modifying protein 1 (RAMP1) (McLatchie et al., 
1998). Despite its atypical heterodimeric composition the !CGRP-receptor shares the 
common features of most classical 7TM-receptors including G-protein coupled signaling via 
activation of the adenlyatcyclase or the "# G-protein dimer (Meens et al., 2011). Interestingly, 
the !CGRP-receptor interacts also with "-arrestin 2 (Hilairet et al., 2001). "-arrestin signaling 
promotes cardio-protection in situations of chronic catecholamine or mechanical stresses 
whereas incessant G-protein dependent signaling is known to confer cardiotoxic effects 
(Whalen et al., 2010). Indeed, "-arrestin-biased ligands of the "1-adrenergic receptor that is 
always stimulated during cardiac stresses might be cardio-protective and promising for heart 
failure therapy (Whalen et al., 2010). Of note, there are two types of 7TM G-protein coupled 
receptors (GPCRs), those forming stable signaling complexes with "-arrestin (class B 
receptors) and those able to form only transient signaling complexes (class A receptors) 
(Shenoy and Lefkowitz, 2011). Thus, co-activation of GPCRs from different classes, while 
recruiting $-arrestins to GPCRs of both types, could yield a preferred binding of arrestin 
partner proteins by high affinity receptors of the B class. Cardiac !CGRP-receptors might 
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also recruit "-arrestin to the membrane as it has been shown for numerous 7TM-receptors 
(DeWire et al., 2007) and this way facilitate shifting signaling of "1-adrenergic receptors 
towards "-arrestin dependent pathways. In line with this "-arrestin recruitment hypothesis is 
the fact that despite the interaction of "-arrestin with the !CGRP-receptor (Hilairet et al., 
2001) the latter lacks the highly conserved "-arrestin binding motifs of other GPCRs (Oakley 
et al., 2001). Possibly the interaction between !CGRP-receptor and "-arrestin is even weaker 
than that of class A GPCRs and thus more easily re-direct "-arrestin to class B GPCRs 
receptors such as the "1-adrenergic receptor. 
During exercise the mechanical and chemical status of exercising skeletal muscles is 
continuously monitored (Boushel, 2010) by A" and C fibers (Mitchell et al., 1983, Amann et 
al., 2011). In these nociceptor-like, chemically sensitive fibers Transient Receptor Potential, 
vanilloid family member 1 channels induce !CGRP release when stimulated e.g. by reduced 
tissue pH (Kichko and Reeh, 2009, Jonhagen et al., 2006), which in turn might trigger the 
previously shown exercise-induced rise of plasma !CGRP concentrations (Schifter et al., 
1995, Lind et al., 1996, Hasbak et al., 2002). Interestingly, Schifter et al. (Schifter et al., 
1995) report for the same workload a marginal an inverse correlation between increasing 
!CGRP plasma levels and training conditions indicating that in well-trained subjects 
muscular !CGRP release is reduced similar to sympathetic activity (Hautala et al., 2008). 
Thus, at the same workload muscles of untrained individuals may release more !CGRP or, in 
other words, exhibit a higher endocrine activity. In this context it should be noted that 
!CGRP elevates directly, beta-receptor- and sympathetic nervous system-independent atrial 
force as well as contraction and relaxation speed (Ishikawa et al., 1988). This finding is well 
in line with data from para- and tetraplegic patients where leg exercise in these individuals 
increases Q even in the absence of a functional sympathetic nervous system (Dela et al., 
2003). Thus, endocrine coupling between exercising skeletal muscles and heart evidently act 
in parallel to the sympathetic nervous system-dependent metaboreflex. Interestingly, in 
patients with spinal cord injury leg exercise increased plasma !CGRP levels and this was 
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more pronounced in tetraplegic than paraplegic patients (Kjaer et al., 2001). To interpret these 
data one should emphasize that paraplegic patients exhibit residual sympathetic nervous 
system activity whereas tetraplegic individuals are devoid of it. These observations therefore 
also suggest the potential of !CGRP to compensate even gradually during exercise for the 
loss of the sympathetic nervous system. 
Another physiological condition associated with a considerable increase of Q also might be of 
interest in this context. Plasma concentrations of !CGRP increase parallel to its systemic and 
regional hemodynamic effects during pregnancy (Gangula et al., 2001). In addition, female 
rodents are more susceptible for the development of physiological heart hypertrophy than 
males (De Bono et al., 2006, Konhilas et al., 2004). Pregnancy requires a marked increase in 
Q within a relative short time period to fuel the rapid fetal growth but to also fully maturate 
the uterine arcade as an essential prerequisite of the high perfusion of the gravid uterus 
(Gassmann et al., 2008). Indeed, next to exercise, pregnancy is another albeit more chronic 
non-pathological condition that results in physiological cardiac hypertrophy without a fetal 
gene reprogramming pattern (Eghbali et al., 2006). Thus, !CGRP appears to maintain also 
cardiac hypertrophy during pregnancy within the boundaries of a physiological phenotype. 
Finally, it is noteworthy that in addition to !CGRP also adrenomedullin binds and activates 
the CLR when the latter is associated with the receptor activity modifying protein 2 (RAMP2) 
or RAMP3 instead of RAMP1, which defines the !CGRP specificity of the CLR (McLatchie 
et al., 1998). Adrenomedullin is essential for embryonic heart development because deletion 
of either RAMP2 or adrenomedullin results in lethal vascular, lymphatic and cardiac 
malformations (Fritz-Six et al., 2008, Shindo et al., 2001). On the other hand deletion of 
!CGRP is not lethal (Lu et al., 1999). Regarding adrenomedullin plasma concentrations in 
response to exercise data are somewhat conflicting. Some studies found no changes of the 
adrenomedullin plasma concentration with exercise (Poveda et al., 1998), others a slight 
although significant increase in plasma adrenomedullin (Hasbak et al., 2002), e.g. at 90 min – 
but not 30 min – of submaximal exercise (Krzeminski et al., 2006). In our training protocol 
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one session lasted 45 min. According to the findings of Krzemi%ski et al. (Krzeminski et al., 
2006) this time is most likely too short to result in an increased adrenomedullin plasma 
concentration. However, the same group also reported an about 50% increase in 
adrenomedullin plasma concentration with 2x 3min grip exercise (30% of maximal voluntary 
contraction) (Krzeminski et al., 2002) that activates much less muscle mass than the bicycle 
ergometer exercise of their later study (Krzeminski et al., 2006). This discrepancy, regarding 
both the higher total increase in adrenomedullin as well as the much faster response in hand 
grip exercise, remains unclear. In contrast, data regarding increased CGRP plasma 
concentration during exercise are much more consistent (Schifter et al., 1995, Lind et al., 
1996, Hasbak et al., 2002) 
Adrenomedullin is a strong vasodilatator especially in the pulmonary vasculature and it has 
been shown that adrenomedullin inhalation improves exercise performance in patients 
suffering from pulmonary hypertension (Nagaya et al., 2004). This effect was however not 
ascribed to a direct positive inotropic effect of adrenomedullin on the heart but rather to a 
reduced vascular resistance in the pulmonary circulation, which in turn reduces cardiac 
afterload, and consequently improves cardiac index (Nagaya et al., 2004). Another study 
demonstrates an inotropic effect of adrenomedullin in isolated perfused rat hearts (Szokodi et 
al., 1998). However, the effective dosages in this study were at least 1 to 2 orders of 
magnitude higher than the plasma concentrations found in man under rest or exercise 
(Krzeminski et al., 2006, Krzeminski et al., 2002, Hasbak et al., 2002) and at high 
concentrations adrenomedullin might also activate CGRP receptors (Liao et al., 2013). 
In summary, !CGRP appears to be the key hormonal signal that promotes physiological 
cardiac hypertrophy by allowing the heart to distinguish physiological, exercise-induced from 
pathological stresses. This also could explain why endurance sport is quite favorable to heart 
failure patients (Ventura-Clapier, 2009). Although our findings could entice athletes to use 
!CGRP for improving their endurance capacity, future !CGRP agonists might inhibit in 
patients suffering from various diseases the emergence of pathological cardiac hypertrophy. 
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Such a treatment option could be especially beneficial for individuals who cannot do 
endurance sport. 
 
Acknowledgements 
The authors thank Viktoria Gloy for her assistance with the CT measurements and Ron B. 
Emeson for sharing his !CGRP-/- mice with us. This work was supported by the Swiss 
National Science Foundation (SNF, 310030_120321, to J.V.). 
 
Conflict of interest 
none. 
 
 20 
References 
 
Amann, M., Runnels, S., Morgan, D. E., Trinity, J., Fjeldstad, A., Wray, D. W., et al. 2011. On 
the Contribution of Group Iii and Iv Muscle Afferents to the Circulatory Response to 
Rhythmic Exercise in Humans. J Physiol, 589, 3855-3866. 
Andersen, P. & Saltin, B. 1985. Maximal perfusion of skeletal muscle in man. J Physiol, 366, 
233-49. 
Bell, D., Schluter, K. D., Zhou, X. J., McDermott, B. J. & Piper, H. M. 1995. Hypertrophic 
effects of calcitonin gene-related peptide (CGRP) and amylin on adult mammalian 
ventricular cardiomyocytes. J Mol Cell Cardiol, 27, 2433-43. 
Bell, D., Tamamori, M., Marumo, F., Hiroe, M., McDermott, B. J. & Ito, H. 1997. Calcitonin 
gene-related peptide (CGRP) increases cell surface area and induces expression of 
skeletal alpha-actin ANP mRNA in hypertrophying neonatal cardiomyocytes. Regul 
Pept, 71, 1-7. 
Boushel, R. 2010. Muscle metaboreflex control of the circulation during exercise. Acta Physiol 
(Oxf), 199, 367-83. 
Carver, W., Nagpal, M. L., Nachtigal, M., Borg, T. K. & Terracio, L. 1991. Collagen expression 
in mechanically stimulated cardiac fibroblasts. Circ Res, 69, 116-22. 
De Bono, J. P., Adlam, D., Paterson, D. J. & Channon, K. M. 2006. Novel quantitative 
phenotypes of exercise training in mouse models. Am J Physiol Regul Integr Comp 
Physiol, 290, R926-34. 
De Castro, S., Caselli, S., Maron, M., Pelliccia, A., Cavarretta, E., Maddukuri, P., et al. 2007. 
Left ventricular remodelling index (LVRI) in various pathophysiological conditions: a 
real-time three-dimensional echocardiographic study. Heart, 93, 205-9. 
Dela, F., Mohr, T., Jensen, C. M., Haahr, H. L., Secher, N. H., Biering-Sorensen, F., et al. 
2003. Cardiovascular control during exercise: insights from spinal cord-injured 
humans. Circulation, 107, 2127-33. 
DeWire, S. M., Ahn, S., Lefkowitz, R. J. & Shenoy, S. K. 2007. Beta-arrestins and cell 
signaling. Annu Rev Physiol, 69, 483-510. 
Eghbali, M., Wang, Y., Toro, L. & Stefani, E. 2006. Heart hypertrophy during pregnancy: a 
better functioning heart? Trends Cardiovasc Med, 16, 285-91. 
Eleftheriades, E. G., Durand, J. B., Ferguson, A. G., Engelmann, G. L., Jones, S. B. & 
Samarel, A. M. 1993. Regulation of procollagen metabolism in the pressure-
overloaded rat heart. J Clin Invest, 91, 1113-22. 
Fisher, L. A., Kikkawa, D. O., Rivier, J. E., Amara, S. G., Evans, R. M., Rosenfeld, M. G., et 
al. 1983. Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related 
peptide. Nature., 305, 534-536. 
Franco-Cereceda, A., Henke, H., Lundberg, J. M., Petermann, J. B., Hokfelt, T. & Fischer, J. 
A. 1987. Calcitonin gene-related peptide (CGRP) in capsaicin-sensitive substance P-
immunoreactive sensory neurons in animals and man: distribution and release by 
capsaicin. Peptides., 8, 399-410. 
Fritz-Six, K. L., Dunworth, W. P., Li, M. & Caron, K. M. 2008. Adrenomedullin signaling is 
necessary for murine lymphatic vascular development. J Clin Invest, 118, 40-50. 
Gangula, P. R., Zhao, H., Wimalawansa, S. J., Supowit, S. C., DiPette, D. J. & Yallampalli, C. 
2001. Pregnancy and steroid hormones enhance the systemic and regional 
hemodynamic effects of calcitonin gene-related peptide in rats. Biol Reprod, 64, 
1776-83. 
Gassmann, M., Manini, A., Stallmach, T., Saam, B., Kuhn, G., Grenacher, B., et al. 2008. 
Abortion in mice with excessive erythrocytosis is due to impaired arteriogenesis of the 
uterine arcade. Biol Reprod, 78, 1049-57. 
Guimaraes, G. G., Santos, S. H., Oliveira, M. L., Pimenta-Velloso, E. P., Motta, D. F., Martins, 
A. S., et al. 2012. Exercise induces renin-angiotensin system unbalance and high 
collagen expression in the heart of Mas-deficient mice. Peptides, 38, 54-61. 
Hasbak, P., Lundby, C., Olsen, N. V., Schifter, S. & Kanstrup, I. L. 2002. Calcitonin gene-
related peptide and adrenomedullin release in humans: effects of exercise and 
hypoxia. Regul. Pept., 108, 89-95. 
Hautala, A. J., Kiviniemi, A. M., Makikallio, T. H., Tiinanen, S., Seppanen, T., Huikuri, H. V., et 
al. 2008. Muscle sympathetic nerve activity at rest compared to exercise tolerance. 
Eur J Appl Physiol, 102, 533-8. 
 21 
Henke, H., Tschopp, F. A. & Fischer, J. A. 1985. Distinct binding sites for calcitonin gene-
related peptide and salmon calcitonin in rat central nervous system. Brain Res, 360, 
165-71. 
Hilairet, S., Belanger, C., Bertrand, J., Laperriere, A., Foord, S. M. & Bouvier, M. 2001. 
Agonist-promoted internalization of a ternary complex between calcitonin receptor-
like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J Biol 
Chem, 276, 42182-90. 
Hillebrand, J. J., Langhans, W. & Geary, N. 2010. Validation of computed tomographic 
estimates of intra-abdominal and subcutaneous adipose tissue in rats and mice. 
Obesity (Silver Spring), 18, 848-53. 
Hoppeler, H., Luthi, P., Claassen, H., Weibel, E. R. & Howald, H. 1973. The ultrastructure of 
the normal human skeletal muscle. A morphometric analysis on untrained men, 
women and well-trained orienteers. Pflugers Arch, 344, 217-32. 
Hoppeler, H. & Weibel, E. R. 1998. Limits for oxygen and substrate transport in mammals. J 
Exp Biol, 201, 1051-64. 
Huang, M. H., Knight III, P. R. & Izzo Jr, J. L. 1999. Ca2+-induced Ca2+ release involved in 
positive inotropic effect mediated by CGRP in ventricular myocytes. Am. J. Physiol., 
276, R259-R264. 
Hullin, R., Asmus, F., Ludwig, A., Hersel, J. & Boekstegers, P. 1999. Subunit expression of 
the cardiac L-type calcium channel is differentially regulated in diastolic heart failure 
of the cardiac allograft. Circulation, 100, 155-63. 
Ishikawa, T., Okamura, N., Saito, A., Masaki, T. & Goto, K. 1988. Positive inotropic effect of 
calcitonin gene-related peptide mediated by cyclic AMP in guinea pig heart. Circ Res, 
63, 726-34. 
Jirkof, P., Cesarovic, N., Rettich, A., Fleischmann, T. & Arras, M. 2012. Individual housing of 
female mice: influence on postsurgical behaviour and recovery. Lab Anim, 46, 325-
34. 
Jonhagen, S., Ackermann, P., Saartok, T. & Renstrom, P. A. 2006. Calcitonin gene related 
peptide and neuropeptide Y in skeletal muscle after eccentric exercise: a 
microdialysis study. Br. J. Sports. Med., 40, 264-267. 
Kabaeva, Z., Zhao, M. & Michele, D. E. 2008. Blebbistatin extends culture life of adult mouse 
cardiac myocytes and allows efficient and stable transgene expression. Am J Physiol 
Heart Circ Physiol, 294, H1667-74. 
Katori, T., Hoover, D. B., Ardell, J. L., Helm, R. H., Belardi, D. F., Tocchetti, C. G., et al. 2005. 
Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional 
sympatho-stimulation and is blunted in congestive heart failure. Circ. Res., 96, 234-
243. 
Kichko, T. I. & Reeh, P. W. 2009. TRPV1 controls acid- and heat-induced calcitonin gene-
related peptide release and sensitization by bradykinin in the isolated mouse trachea. 
Eur J Neurosci, 29, 1896-904. 
Kjaer, M., Mohr, T., Dela, F., Secher, N., Galbo, H., Olesen, H., et al. 2001. Leg uptake of 
calcitonin gene-related peptide during exercise in spinal cord injured humans. Clin 
Physiol, 21, 32-8. 
Konhilas, J. P., Maass, A. H., Luckey, S. W., Stauffer, B. L., Olson, E. N. & Leinwand, L. A. 
2004. Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ 
Physiol, 287, H2768-76. 
Krzeminski, K., Kruk, B., Wojcik-Ziolkowska, E., Kozera, J., Cybulski, G. & Nazar, K. 2002. 
Effect of static handgrip on plasma adrenomedullin concentration in patients with 
heart failure and in healthy subjects. J Physiol Pharmacol, 53, 199-210. 
Krzeminski, K., Mikulski, T. & Nazar, K. 2006. Effect of prolonged dynamic exercise on 
plasma adrenomedullin concentration in healthy young men. J Physiol Pharmacol, 
57, 571-81. 
Kunz, T. H., Scott, M., Ittner, L. M., Fischer, J. A., Born, W. & Vogel, J. 2007. Calcitonin gene-
related peptide-evoked sustained tachycardia in calcitonin receptor-like receptor 
transgenic mice is mediated by sympathetic activity. Am J Physiol Heart Circ Physiol, 
293, H2155-60. 
Liao, S. B., Cheung, K. H., Cheung, M. P., To, Y. T., O, W. S. & Tang, F. 2013. 
Adrenomedullin increased the short-circuit current in the pig oviduct through chloride 
channels via the CGRP receptor: mediation by cAMP and calcium ions but not by 
nitric oxide. Biol Reprod, 89, 99. 
 22 
Lind, H., Brudin, L., Lindholm, L. & Edvinsson, L. 1996. Different levels of sensory 
neuropeptides (calcitonin gene-related peptide and substance P) during and after 
exercise in man. Clin. Physiol., 16, 73-82. 
Lindsay, M. M. & Dunn, F. G. 2007. Biochemical evidence of myocardial fibrosis in veteran 
endurance athletes. Br J Sports Med, 41, 447-52. 
Lopez-De Leon, A. & Rojkind, M. 1985. A simple micromethod for collagen and total protein 
determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem, 
33, 737-43. 
Lu, J. T., Son, Y. J., Lee, J., Jetton, T. L., Shiota, M., Moscoso, L., et al. 1999. Mice lacking 
alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and 
neuromuscular development. Mol. Cell. Neurosci., 14, 99-120. 
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., et al. 1998. 
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like 
receptor. Nature., 393, 333-339. 
Meens, M. J., Mattheij, N. J., van Loenen, P. B., Spijkers, L. J., Lemkens, P., Nelissen, J., et 
al. 2011. G protein betagamma-subunits in vasorelaxing and anti-endothelinergic 
effects of calcitonin gene-related peptide. Br J Pharmacol. 
Mitchell, J. H., Kaufman, M. P. & Iwamoto, G. A. 1983. The exercise pressor reflex: its 
cardiovascular effects, afferent mechanisms, and central pathways. Annu Rev 
Physiol, 45, 229-42. 
Mulderry, P. K., Ghatei, M. A., Rodrigo, J., Allen, J. M., Rosenfeld, M. G., Polak, J. M., et al. 
1985. Calcitonin gene-related peptide in cardiovascular tissues of the rat. 
Neuroscience, 14, 947-54. 
Nagaya, N., Kyotani, S., Uematsu, M., Ueno, K., Oya, H., Nakanishi, N., et al. 2004. Effects of 
adrenomedullin inhalation on hemodynamics and exercise capacity in patients with 
idiopathic pulmonary arterial hypertension. Circulation, 109, 351-6. 
Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S. & Caron, M. G. 2001. Molecular 
determinants underlying the formation of stable intracellular G protein-coupled 
receptor-beta-arrestin complexes after receptor endocytosis*. J Biol Chem, 276, 
19452-60. 
Perrino, C., Naga Prasad, S. V., Mao, L., Noma, T., Yan, Z., Kim, H. S., et al. 2006. 
Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction 
and vascular rarefaction. J Clin Invest, 116, 1547-60. 
Poveda, J. J., Berrazueta, J. R., Ochoteco, A., Montalban, C., Garcia-Unzueta, M. T., 
Fernandez, C., et al. 1998. Age-related responses of vasoactive factors during acute 
exercise. Horm Metab Res, 30, 668-72. 
Riddle, D. R., Gutierrez, G., Zheng, D., White, L. E., Richards, A. & Purves, D. 1993. 
Differential metabolic and electrical activity in the somatic sensory cortex of juvenile 
and adult rats. J. Neurosci., 13, 4193-4213. 
Rosenblatt, J. D., Kuzon, W. M., Jr., Plyley, M. J., Pynn, B. R. & McKee, N. H. 1987. A 
histochemical method for the simultaneous demonstration of capillaries and fiber type 
in skeletal muscle. Stain Technol, 62, 85-92. 
Schifter, S., Breum, L., Niclasen, B., Vollmer-Larsen, A., Rasmussen, H. S. & Graff-Larsen, 
O. 1995. Calcitonin gene-related peptide during exercise and training. Horm. Metab. 
Res., 27, 473-475. 
Schmelz, M. & Petersen, L. J. 2001. Neurogenic inflammation in human and rodent skin. 
News Physiol Sci, 16, 33-7. 
Schuler, B., Arras, M., Keller, S., Rettich, A., Lundby, C., Vogel, J., et al. 2010. Optimal 
hematocrit for maximal exercise performance in acute and chronic erythropoietin-
treated mice. Proc Natl Acad Sci U S A, 107, 419-23. 
Shenoy, S. K. & Lefkowitz, R. J. 2011. beta-Arrestin-mediated receptor trafficking and signal 
transduction. Trends Pharmacol Sci, 32, 521-33. 
Shindo, T., Kurihara, Y., Nishimatsu, H., Moriyama, N., Kakoki, M., Wang, Y., et al. 2001. 
Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin 
gene. Circulation., 104, 1964-1971. 
Sigrist, S., Franco-Cereceda, A., Muff, R., Henke, H., Lundberg, J. M. & Fischer, J. A. 1986. 
Specific receptor and cardiovascular effects of calcitonin gene-related peptide. 
Endocrinology, 119, 381-9. 
 23 
Szokodi, I., Kinnunen, P., Tavi, P., Weckstrom, M., Toth, M. & Ruskoaho, H. 1998. Evidence 
for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new 
inotropic peptide. Circulation, 97, 1062-70. 
Ventura-Clapier, R. 2009. Exercise training, energy metabolism, and heart failure. Appl 
Physiol Nutr Metab, 34, 336-9. 
Weber, K. T., Brilla, C. G. & Janicki, J. S. 1993. Myocardial fibrosis: functional significance 
and regulatory factors. Cardiovasc Res, 27, 341-8. 
Weber, K. T., Janicki, J. S., Shroff, S. G., Pick, R., Chen, R. M. & Bashey, R. I. 1988. 
Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate 
myocardium. Circ Res, 62, 757-65. 
Whalen, E. J., Rajagopal, S. & Lefkowitz, R. J. 2010. Therapeutic potential of beta-arrestin- 
and G protein-biased agonists. Trends Mol Med, 17, 126-39. 
Zeller, K., Duelli, R., Vogel, J., Schrock, H. & Kuschinsky, W. 1995. Autoradiographic analysis 
of the regional distribution of Glut3 glucose transporters in the rat brain. Brain. Res., 
698, 175-179. 
 
 
 24 
 Tables 
 
 
Table 1      
      
TaqMan® Gene Expression Assays used for ddPCR  
      
Gene name 
Gene 
Symbol Reference sequence 
Assay 
location 
Applied 
Biosystems 
reference Label 
Myosin, 
heavy 
polypeptide 
6, cardiac 
muscle, 
alpha 
(variants 1 & 
2) 
Myh6 http://www.ncbi.nlm.nih.gov/nuccore/NM_001164171.1 http://www.ncbi.nlm.nih.gov/nuccore/NM_010856.4 
2635 
2571 Mm00440359_m1 FAM 
Myosin, 
heavy 
polypeptide 
7, cardiac 
muscle, beta 
Myh7 http://www.ncbi.nlm.nih.gov/nuccore/NM_080728.2 5095 Mm01319006_g1 FAM 
Natriuretic 
peptide type 
A 
Nppa http://www.ncbi.nlm.nih.gov/nuccore/NM_008725.2 209 Mm01255747_g1 FAM 
Calsequestrin 
1 Casq1 http://www.ncbi.nlm.nih.gov/nuccore/NM_009813.2 564 Mm00486725_m1 VIC 
Collagen I Col1a1 http://www.ncbi.nlm.nih.gov/nuccore/NM_007742.3 4071 Mm00801666_g1 FAM 
Collagen III Col3a1 http://www.ncbi.nlm.nih.gov/nuccore/NM_009930.2 4460 Mm01254476_m1 FAM 
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Table 2         
         
Blood parameters (male mice)         
 aCGRP-/- BL6 BL6xDBA2 CLR-tg 
 mean ±SD (n=5) mean ±SD (n=4) mean ±SD (n=4) mean ±SD (n=6) 
          
hematocrit (%) 46.0 ±1.1 45.9 ±2.1 46.8 ±1.9 47.0 ±1.7 
hemoglobin (g/dl) 15.0 ±0.3 14.9 ±0.4 16.1 ±1 16.0 ±0.4 
pH 7.4 ±0.04 7.3 ±0.03 7.3 ±0.03 7.3 ±0.03 
pO2 (mmHg) 105.1 ±9.9 92.5 ±10.3 94.8 ±6.8 98.7 ±4.8 
pCO2 (mmHg) 44.2 ±2.8 36.8 ±7 33.0 ±2.8 35.4 ±2 
base excess (mmol/L) -0.7 ±2.1 -4.3 ±4 -7.1 ±0.4 -6.7 ±1.2 
O2 saturation (%) 96.7 ±3 92.0 ±2 93.6 ±1 94.7 ±2 
          
Blood volume (!l) 2667.8 ±175 2551.2 ±553 1871.8 ±98 1915.8 ±111 
Blood volume (% of body weight) 10.3 ±0.9 10.0 ±1.1 9.7 ±0.2 9.8 ±0.8 
          
total hemoglobin (g) 0.399 ±0.02 0.377 ±0.08 0.301 ±0.01 0.307 ±0.02 
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Table 3           
           
Basal values in awake male mice subsequently used for testing spontaneous exercise performance (cf. Fig. 1) 
 aCGRP-/- BL6 CLR-tg BL6xDBA2 
BL6xDBA2 
+CGRP(8-37) 
 
mean ±SD 
(n=11) 
mean ±SD 
(n=9) 
mean ±SD 
(n=9) 
mean ±SD 
(n=8) 
mean ±SD 
(n=8) 
            
Weight (g) 24.5 ±2.8 26.2 ±1.9 26.6 ±1.4 26.0 ±1.8 26.5 ±1.8 
            
VO2 (ml/min) 50.0 ±3 50.6 ±1.8 47.6 ±2.4 49.0 ±2.3 50.0 ±1 
respiratory 
exchange ratio 0.82 ±0.01 0.81 
±0.0
02 0.81 ±0.01 0.82 ±0.02 0.82 ±0.01 
mean arterial 
blood pressure 
(mmHg) 107.8 ±7.2 111.7 ±4.2 104.2 ±2.3 104.3 ±8.3 109.8 ±5.5 
heart rate (min-1) 510 ±44 540 ±37 506 ±49 509 ±40 525 ±37 
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Table 4         
         
Morphologic characteristics of skeletal muscle and heart of male mice      
 aCGRP-/- BL6 CLR-tg BL6xDBA2 
 mean ±SD mean ±SD mean ±SD mean ±SD 
Skeletal muscle          
type II fibers, gastrocnemius (%, ATPase) 63.0 ±13 67.0 ±14 74.0 ±10 68.0 ±10 
oxidative fibers, tibialis ant. (%, SDH) 47.0 ±11 43.0 ±13 47.0 ±14 47.2 ±16 
capillary contacts 6.3 ±1.3 6.0 ±1.4 6.1 ±2.1 6.4 ±1.8 
         
Heart          
heart index, normalized to body weight (mg/g) 4.76 ±0.3* 5.64 ±0.66 5.39 ±0.3* 4.83 ±0.3 
heart index, normalized to tibia length (mg/cm) 0.067 ±0.01*** 0.085 ±0.01 0.080 ±0.01*** 0.064 ±0.01 
cardiac myocyte volume (*104 fl) 1.18 ±0.15* 1.57 ±0.16 2.76 ±0.63 2.26 ±0.4 
cardiac myocyte cross sectional area (*102 !m2) 3.45 ±1.3*** 4.49 ±1.8 4.95 ±2.1*** 3.35 ±1.6 
         
Cardiac myocytes          
total mitochondria volume / fiber volume (%) 37.39 ±0.48 37.36 ±1.57 36.33 ±1.34 36.43 ±2.15 
nucleus volume / fiber volume (%) 1.38 ±0.06 0.95 ±0.12 0.86 ±0.22 0.38 ±0.001 
intramyocellular lipid volume / fiber volume (%) 0.40 ±0.13 0.28 ±0.09 0.32 ±0.15 0.45 ±0.07 
myofibril volume / fiber volume (%) 55.32 ±0.1 56.50 ±1.57 56.93 ±2.92 57.42 ±1.33 
remaning fiber volume (%) 5.51 ±0.77 4.92 ±0.21 5.56 ±1.21 5.31 ±0.89 
         
*=p<0.05, ***=p<0.001; genetically modified mice compared to their respective wt control 
n = 5 for muscle analysis, n = 6 for heart index, n = 4 for other measurements 
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Table 5         
         
Spontaneous activity during 24h of observation and body fat content (females) 
 aCGRP-/- BL6 CLR-tg BL6xDBA2 
 mean ±SD mean ±SD mean ±SD mean ±SD 
          
daily activity (h), n = 8 14.16 ±0.85*** 13.23 ±0.82** 9.89 ±1.37 10.93 ±1.52 
          
body fat (%), n= 6 7.7 ±2.5*** 9.6 ±2.9* 19.5 ±5.3 19.9 ±8.6 
         
         
* = p<0.05 vs. BL6xDBA2, ** = p<0.01 vs. BL6xDBA2, *** = p<0.001 vs. CLR-tg 
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Legends to figures 
 
Figure 1: Spontaneous maximum exercise capacity is decreased in CGRP-/- mice and 
CGRP(8-37) treated wt mice but increased in CLR-tg mice.  
(a) CLR-tg mice displayed higher and !CGRP-/- mice lower VO2max compared to matched wt 
controls. Injection of 20nmol of the !CGRP antagonist CGRP(8-37) into BL6xDBA2 prior to 
the VO2max test decreased their performance (BL6xDBA2 + CGRP(8-37)). (b) Time to 
exhaustion (TTE) for CLR-tg mice was delayed by approximately 45% while !CGRP-/- mice 
were already exhausted at about 70% shortened time periods. Accordingly, CGRP(8-37)-
treatment reduced TTE in BL6xDBA2 by about 34%. (c) The respiratory exchange ratio 
measured at VO2max and did not differ between the different experimental groups indicating 
that all animals reached always the same level of exhaustion at VO2max. Compared to their wt 
controls, mean arterial blood pressure (MAP, d) was higher in CLR-tg mice, lower in 
BL6xDBA2 mice treated with CGRP(8-37) and unchanged in  !CGRP-/- mice whereas heart 
rate (HR, e) was lower in !CGRP-/- mice only. O2 pulse (f) as a measure for stroke volume 
and rate pressure product (G) representing myocardial oxygen consumption were altered as 
VO2max and TTE. Means ±SD of n male mice as indicated on the columns. Kruskal-Wallis 
test, *** = p<0.001 vs. BL6; † = p<0.05, †† = p<0.01, ††† = p<0.001 vs. BL6xDBA2. 
 
Figure 2: Enhanced !CGRP signaling augments the size of cultured adult cardiac myocytes 
and is required for development of exercise-induced myocardial hypertrophy.  
(a) Cells cultured for 3.5 days with 250nM !CGRP (gray column) were 11% compared to 
cells cultured without the peptide (white column). In contrast, cultured ventricular myocytes 
treated for the same time with 250nM calcitonin (b, gray column) had the same size as cells 
cultured without calcitonin (white column). Accordingly, cross sectional area (c) as well as 
myocardial volume (d) was significantly increased by 3 weeks of endurance training with five 
45-min units per week in PBS treated mice (black columns) but not altered at all in mice 
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treated with CGRP(8-37) (white columns). (e) In contrast to PBS treated mice (black 
column), CGRP(8-37) treated mice (white column) exhibited an 21% increased (p = 0.076) 
ratio between enddiastolic volume (EDV) and myocardial volume (MV) as it is typical for 
pathological heart hypertrophy (De Castro et al., 2007). Means ±SD of n male mice as 
indicated on the columns. Students t-test for paired samples,  # = p<0.05 in (d, e) vs. pre-
training, * = p<0.05, ** = p<0.01, *** = p<0.001 in (c-e) vs. PBS group. 
 
Figure 3: Density of !CGRP receptors is lowered in atria of "CGRP-/- mice but elevated in 
the whole heart of CLR-tg animals. 
Quantitative receptor- (a) and immunautoradiography (b) for CGRP and example 
autoradiograms of each line (atria marked with arrows heads). Bar graphs indicate 8-bit gray 
values (0 = black, 255 = white). The right of each double bar represents the data for the atria 
and the left of each pair represents the ventricles. (a) !CGRP binding was higher in the atria 
of all lines as evident from the lower gray values. Compared to their wild type controls 
(BL6xDBA2), CLR-tg had significantly more binding sites in atria as well as ventricles. 
!CGRP deficient mice had the same density of binding sites in ventricles but significantly 
less in the atria in comparison to BL6. (b) CGRP immunreactivity was higher in atria and 
compared with all other lines markedly decreased in !CGRP-/- mice (cf. brighter audiogram). 
BL6xDBA2, CLR-tg and BL6 did not differ from each other. Means ±SD of 5-6 male mice 
per group. Students t-test for unpaired samples,  * = p<0.05, ** = p<0.01, *** = p<0.001. 
 
Figure 4: !CGRP deficiency promotes a fetal gene expression profile in the heart. 
(a) Copy number ratio of myh7/myh6 and Nppa/calsequestrin in hearts of naïve mice in 
comparison to matched wild type controls measured with ddPCR. In !CGRP-/- mice the 
pattern resembles fetal gene expression reprogramming that is typical for pathological 
hypertrophy with a significant increase of the myh7/myh6 expression ratio and Nppa 
expression. In contrast, in CLR-tg mice both markers tended to be reduced. (b) Compared to 
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BL6 mice treated with PBS prior to each training session CGRP(8-37) treatment tended to 
increase myh7/myh6 expression ratio and Nppa expression (Fig. 4b). In sedentary mice these 
markers were completely independent of treatment with PBS or CGRP(8-37). Means ±SD of 
n male mice as indicated on the columns. Students t-test for unpaired samples, * = p<0.05. 
 
 
fig. 1
VO2max
0
110
120
130
140
150
160
170
O
2
 c
o
n
su
m
p
ti
o
n
(m
l/
m
in
/
k
g
)
N=9
†††
(a)
(b)
(c)
TTE (constant load, 80% of VO2max)
0
20
40
60
80
100
120
ti
m
e
 (
m
in
)
RER
0
0.75
0.8
0.85
0.9
0.95
1
1.05
1.1
N=11 N=9
***
***
N=8 N=8
V
C
O
2
/
V
O
2
(d)
(e)
(f)
(g)
0
85000
90000
95000
100000
105000
110000
115000
H
R
 t
im
e
s 
M
A
P
(m
m
H
g
 /
 m
in
)
Rate pressure product
O2-pulse
0
0.12
0.14
0.16
0.18
0.2
0.22
0.24
0.26
V
O
2
m
a
x 
p
e
r 
 h
e
a
rt
 b
e
a
t
(m
l 
/
 m
in
 /
 k
g
)
HR
0
700
720
740
760
780
800
820
b
e
a
ts
 (
m
in
-1
)
MAP
0
70
80
90
100
110
120
130
140
150
160
p
re
ss
u
re
 (
m
m
H
g
)
***
!CGRP-/-
BL6
CLR-tg
BL6xDBA2
BL6xDBA2 + CGRP(8-37)
N=9N=11 N=9 N=8 N=8
N=9N=11 N=9 N=8 N=8
N=9N=11 N=9 N=8 N=8
N=9N=11 N=9 N=8 N=8
N=9N=11 N=9 N=8 N=8
N=9N=11 N=9 N=8 N=8
†††
††
†
††
†††
†
†
(d)
-10
-5
0
5
10
15
20
25
***
ch
a
n
g
e
 i
n
 m
yo
ca
rd
ia
l 
vo
lu
m
e
 v
s.
 p
re
-t
ra
in
in
g
 (
%
)
N=7
N=7
#
fig. 2
(a) (b)
- !CGRP + !CGRP
ce
ll
 v
o
lu
m
e
 (
fl
) *
0
10000
12000
14000
16000
- calcitonin + calcitonin
ce
ll
 v
o
lu
m
e
 (
fl
)
0
13000
14000
15000
16000
17000
N=6 N=6 N=3N=3
(e)
PBS    CGRP(8-37) 
!
 r
e
m
o
d
e
li
n
g
 i
n
d
e
x
 (
m
g
/
"
l)
*
-0.35
-0.3
-0.25
-0.2
-0.15
-0.1
-0.05
0
0.05
0.1
N=7
N=7
#
PBS    CGRP(8-37) 
(c)
cr
o
ss
 s
e
ct
io
n
a
l 
a
re
a
 (
*
1
0
2
 "
m
2
)
PBS    CGRP(8-37) 
0
1
2
3
4
5
**
N=7 N=7
(a)
0
20
40
60
80
100
120
140
125I-CGRP binding 
g
ra
y 
va
lu
e
***
fig. 3
(b)
0
20
40
60
80
100
120
140
g
ra
y 
va
lu
e
160
CGRP immun-autoradiography 
CLR-tg BL6xDBA2BL6_alpha-CGRP-/- BL6_wt
*
**
**
***
ns
**
***
CLR-tg BL6xDBA2BL6_alpha-CGRP-/- BL6_wt
******
***
***
***
***
A   V A   V A   V A   V
A   V A   V A   V A   V
fig. 4
BL6 +CGRP(8-37)
BL6 +PBS
!CGRP-/-
BL6
CLR-tg
BL6xDBA2
(a)
0
0.002
0.004
0.006
0.008
0.01
0.012
0.014
0.016
co
p
y 
n
u
m
b
e
r 
ra
ti
o
Myh7/Myh6
*
N=5N=5N=6N=5
0
2
4
6
8
10
12
14
Nppa/calsequestrin
co
p
y 
n
u
m
b
e
r 
ra
ti
o
*
N=5N=6N=5 N=5
0
1
2
3
4
5
6
7
collagen III/collagen I
N=5N=6N=5 N=5
co
p
y 
n
u
m
b
e
r 
ra
ti
o
*
(b)
0
0.005
0.01
0.015
0.02
0.025
0.03
N=7 N=7
Myh7/Myh6
N=3 N=3
co
p
y 
n
u
m
b
e
r 
ra
ti
o
Nppa/calsequestrin
trained     sedentary trained       sedentary
0
0.5
1
1.5
2
2.5
3
N=7 N=7 N=3 N=3
co
p
y 
n
u
m
b
e
r 
ra
ti
o
0
0.5
1
1.5
2
2.5
3
3.5
collagen III/collagen I
trained       sedentary
N=7 N=7 N=3 N=3
co
p
y 
n
u
m
b
e
r 
ra
ti
o
